What Is a Hole in the Heart in Babies?

What Is a Hole in the Heart in Babies?

Nobody in that delivery room hands you a guide for this. You’re still figuring out feeding and sleep and then someone says your baby has a hole in the heart. Just like that. It’s a gap between heart chambers that genuinely shouldn’t be sitting there. Some gaps seal up without anyone doing a thing. Others don’t budge. And how much trouble it causes your baby comes down entirely to where that hole is, what size it grew to and what it’s been silently doing to that little heart since before you even knew about it.

“A hole in the heart isn’t always an emergency but it’s never something to watch from a distance without a proper evaluation first,” says Dr. Prashant Bobhate, Pediatric Cardiologist in Mumbai, India.

What Types of Holes in the Heart Actually Show Up in Babies?

This isn’t one thing with one name. That’s the first thing worth knowing. Different holes. Different spots inside the heart. Different amounts of serious. A baby can go home and never need a procedure their whole life.

  • Ventricular Septal Defect (VSD): Most common one doctors see, found between the lower chambers, and genuinely quite a few small ones just close by themselves over the first year with zero intervention from anyone.
  • Atrial Septal Defect (ASD): This one is a quiet hider. It sits between the upper chambers and can go completely undetected for years because nothing in the early stages points anyone toward thinking heart.
  • Patent Ductus Arteriosus (PDA): A vessel that was supposed to close itself down right after birth just didn’t do it and has been sending blood the wrong direction through your baby’s body from day one without anyone catching on.
  • Atrioventricular Septal Defect (AVSD): Upper and lower chambers hit at the same time, crops up more in babies born with Down syndrome, and honestly it nearly always needs surgical repair at some stage.

What type it is, exactly where it lives and what extra work it’s piling onto the heart all feed into the right congenital heart disease treatment decision for your specific child.

What Signs Suggest a Heart Hole Is Causing a Problem in Your Baby?

Weeks go by sometimes. Months even. And parents are still putting it down to a difficult phase or a fussy feeder or just one of those things. 

  • Breathing that looks like genuine hard work: Chest visibly caving in during feeds or breathing way too fast while resting quietly means the heart and lungs aren’t coping the way they should be at this age.
  • Every feed stops halfway and the weight just isn’t going up: Your baby quits before the feed’s done every single time and still isn’t growing. That’s a pattern. Patterns have reasons. This one’s worth finding out.
  • Blue tint sitting around the lips or fingers: That colour on a baby isn’t normal and it isn’t something to watch from home for another few weeks. It means blood oxygen is low and that needs looking at today not later.
  • Same chest infection rolling back in before the last one finished: A hole letting blood into the lungs builds the exact warm wet environment where infections move in, get comfortable and just keep returning no matter what treatment you throw at them.

Parents already watching some of this play out with their own baby should read this piece on how to spot the early signs of heart disease in neonates which goes through what these signs genuinely look like in real life during those first few weeks at home

Why Choose Dr. Prashant Bobhate for Pulmonary Hypertension Treatment in Mumbai?

You don’t want someone who treats your baby like a case number on a list. Dr. Prashant Bobhate is the kind of doctor who actually sits down with you, talks through what’s happening in real language and builds something around your child’s actual situation not a textbook version of it. He trained at Escorts Heart Institute in New Delhi then made a deliberate choice to go to the University of Alberta in Canada specifically to go deeper into this field. His team carried out India’s very first successful Transcatheter Potts Shunt and right now looks after over 400 children on advanced therapy.

📞 Call Now: (+91) 8080 826 898 

A proper evaluation provides clear answers about what the hole is doing and what the right next step actually is for your child.

FAQs

Can a hole in the heart in babies close on its own?

Many small VSDs and PDAs close naturally within the first year of life without requiring any medical or surgical intervention.

Is a hole in the heart always detected during pregnancy scans?

Not always. Fetal echocardiography between 18 to 22 weeks provides the clearest view but smaller defects can still go undetected before birth.

Does a baby with a heart hole always need surgery?

Not necessarily. Small holes are often monitored over time while larger or symptomatic defects require intervention sooner to prevent complications.

Can a child live a normal life after treatment for a heart hole?

Yes. Most children who receive timely and appropriate treatment go on to live fully active and normal lives with no lasting restrictions.

References:

Most Common Cause of Pulmonary Hypertension

Most Common Cause of Pulmonary Hypertension

In most cases of pulmonary hypertension (PH), a left-sided heart disease (for example, heart failure or valve disease) presently exists. With this overworking of the right side of the heart to push blood through the lungs, pulmonary artery pressure is elevated.

“Pulmonary hypertension in children is almost always linked to an underlying cause. Find the cause, treat it correctly and you give that child a genuinely better future,” says Dr. Prashant Bobhate, Pediatric Cardiologist in Mumbai, India.

What Are the Most Common Causes of Pulmonary Hypertension?

Here’s what most families never get explained properly in that first consultation. Pulmonary hypertension doesn’t just decide to show up one morning. Something brought it there. Something that was already quietly happening in the background while life carried on completely normally around it.

  • Congenital heart disease: A structural defect your child was born with is the single biggest driver of pulmonary hypertension in kids and it walks into specialist clinics far more often than any family sitting in that waiting room ever expected it would when they first arrived.
  • Chronic lung conditions: Bronchopulmonary dysplasia just chips away at the lung arteries quietly and steadily every single day until blood pressure crosses a line it was never supposed to cross and doesn’t easily come back down from.
  • Connective tissue disorders: Lupus, scleroderma, things in that family silently eat through pulmonary blood vessel walls for months sometimes before anyone starts connecting those dots to what’s actually happening with the pressure readings.
  • Idiopathic pulmonary arterial hypertension: No reason. No cause anyone can point to. The pressure just keeps climbing on its own and that’s genuinely the version of this that keeps specialists up at night because there’s nothing obvious to go after and fix.

Nearly 40% of childhood pulmonary hypertension traces straight back to congenital heart disease and catching that connection early is honestly what rewrites how the rest of this whole story goes.

What Happens When the Cause Gets Left Without Proper Treatment?

Nobody wants to read this part. But here it is anyway because you came here wanting the real answer not a softened version of it. The cause doesn’t sit quietly and wait for you to get around to dealing with it. It keeps doing what it’s doing. 

  • Right heart breaks down quietly: Beat after beat that right heart keeps pushing against pressure it was never meant to handle and one day it just runs out of road completely and by then the damage has usually been building far longer than anyone realised.
  • Physical life shrinks week by week: What started as getting winded on stairs becomes getting winded sitting still and that progression doesn’t pause for anyone while nothing’s being done to slow it down.
  • Oxygen crashes arrive without warning: Mid-meal, mid-sleep, mid-playing in the garden and they don’t knock before they come in and they can go from worrying to genuinely frightening faster than anyone sitting nearby is prepared for.
  • Other organs start paying quietly too: Kidneys, liver, everything downstream of a heart that’s struggling to circulate properly starts accumulating damage that doesn’t always fully reverse even when the right treatment finally arrives later.

Parents or adults already watching this unfold should read this piece on when is lung transplant necessary for pulmonary hypertension which goes through honestly what happens when pulmonary hypertension progresses and what the options look like at each stage of that road.

Why Choose Dr. Prashant Bobhate for Pulmonary Hypertension Treatment in Mumbai?

Finding the cause isn’t something you want left to someone who sees this a handful of times a year and figures it out carefully as they go. Dr. Prashant Bobhate didn’t stumble into this area. He chose it deliberately and spent over 12 years going deeper into pulmonary hypertension than most cardiologists in India ever have. Trained at Escorts Heart Institute in New Delhi then made a specific trip to the University of Alberta in Canada just for advanced pulmonary hypertension fellowship training.

📞 Call Now: (+91) 8080 826 898 

A proper evaluation gives you real answers about what’s actually driving the pressure in your specific case and what treatment needs to look like going forward.

FAQs

Most common cause in children?

Congenital heart disease is the single most common cause of pulmonary hypertension in children and finding that link early dramatically changes what treatment looks like and how the story goes.

Can the cause be fixed completely?

Sometimes yes. When congenital heart disease is driving the pressure fixing that defect early enough often brings the pulmonary pressure back down to normal alongside it.

Is there a cause that has no treatment?

Idiopathic PAH has no identifiable cause to remove but the pressure itself can be managed effectively with targeted medication and the condition can be kept stable for years with the right specialist involved.

Does stress cause pulmonary hypertension?

No evidence that ordinary stress or lifestyle choices directly cause pulmonary hypertension though certain substances and specific medical conditions are strongly associated with its development.tive normal lives without any lasting limitations whatsoever.

References:

What Is Congenital Heart Disease in Children?

What Is Congenital Heart Disease in Children?

Congenital Heart Defects (CHD) consist of structural defects of the heart which exist at birth and affect approximately one in every 100 newborns. These defects occur when the heart or blood vessels fail to develop completely during the gestation process. There is a wide variety of CHD, from small defects that require monitoring to larger, life-threatening disease. Treatment can include careful monitoring, medications, and surgical intervention.

“Most children with congenital heart disease can live full healthy lives when the condition is caught early and managed with the right plan from the start,” says Dr. Prashant Bobhate, Pediatric Cardiologist in Mumbai, India.

 

What Are the Most Common Types of Congenital Heart Disease in Children?

This isn’t one condition wearing one face. It’s a whole group of structural problems each sitting in a different part of the heart each doing completely different things to blood flow and oxygen delivery.

  • Ventricular Septal Defect (VSD): A hole between the lower chambers letting blood go places it really shouldn’t and while smaller ones sometimes close on their own bigger ones silently pile pressure onto a heart that’s still learning how to work properly.
  • Atrial Septal Defect (ASD): Opening between the upper chambers that is genuinely excellent at hiding because the early signs look like absolutely nothing worrying for a very long time and most families have no idea it’s there.
  • Tetralogy of Fallot (TOF): Four separate problems hitting the heart simultaneously, oxygen in the blood drops and the skin takes on that bluish colour that stops parents cold the very first time they see it on their own child’s face.
  • Transposition of the Great Arteries (TGA): The two main arteries have swapped positions completely and this one doesn’t wait around because it becomes life threatening within the first hours if nobody’s caught it yet.

What type it is, where exactly it sits and what it’s doing to blood flow moment to moment all feed into the right congenital heart disease treatment path for your child specifically.

What Warning Signs Tell You Something Is Wrong With Your Child's Heart?

Weeks go by sometimes. Months even. Because this doesn’t show up wearing a sign. It shows up wearing the face of a tired baby or a child who just seems flat or a kid who always needs to sit down before everyone else does.

  • Breathlessness doing almost nothing: A child struggling to breathe through things other kids their age breeze through without noticing is showing you something that deserves actual investigation rather than watching and hoping it settles on its own.
  • That bluish tint around lips or fingernails: Wrong colour for a child full stop and it means not enough oxygen is making it into the blood which isn’t a watch and see situation from the sofa under any circumstances.
  • Feeding feels like a marathon and weight just isn’t happening: A baby who exhausts themselves trying to get through a feed and still isn’t growing the way the charts say they should has something going on that needs a proper cardiac look not a formula change.
  • Always the tired one, always the one who can’t keep up: If your child is consistently the kid sitting out, crashing early and running on empty while everyone else is still going that pattern is worth chasing down properly.

Parents already watching some of this unfold with their own child should read this piece on how to spot the early signs of heart disease in neonates which goes through what these signs genuinely look like during those first weeks when everything still feels new and uncertain.

Why Choose Dr. Prashant Bobhate for Congenital Heart Disease Treatment in Mumbai?

Your child’s heart isn’t the place for someone who dips into this occasionally between other work. Dr. Prashant Bobhate spent over 12 years going deep into specifically this area. Trained at Escorts Heart Institute in New Delhi then made a deliberate trip to the University of Alberta in Canada just to go further into it. His team carried out India’s very first successful Transcatheter Potts Shunt and right now actively manages over 400 children on advanced therapy. He doesn’t reach for a standard protocol. He sits with what’s actually happening inside your child’s heart and builds entirely from there.

📞 Call Now: (+91) 8080 826 898 

A proper evaluation gives you real answers about what’s happening with your child’s heart and what the right next step actually is.

FAQs

Can congenital heart defects be detected before birth?

Yes fetal echocardiography between 18 to 22 weeks can identify most structural heart defects before your baby has even taken their first breath outside the womb.

Are congenital heart defects genetic?

Some types carry a genetic link but plenty occur without any family history and without any clear reason anyone can point to even after thorough investigation.

Do all congenital heart defects require surgery?

Not always. Some defects close without help or get managed with medication while others do need surgical or catheter based intervention depending on size and severity.

Can children with congenital heart defects live a normal life?

Yes. Most children who get the right treatment at the right time go on to live completely active normal lives without any lasting limitations whatsoever.

References:

Sotatercept: Changing How PAH is Managed, Experience from First Four Patients in India

Sotatercept: Changing How PAH is Managed, Experience from First Four Patients in India

2025 marks a transformative year in the field of pulmonary arterial hypertension (PAH) treatment in India. For those living with this debilitating condition, hope has always been a distant dream. However, the availability of sotatercept—a groundbreaking biologic therapy—has breathed new life into the PAH field. As one of the first institutions to introduce sotatercept for PAH patients in India, we’ve witnessed some of the most remarkable clinical improvements that highlight not just the potential of the drug, but also the resilience and courage of the patients and caregivers who inspire us every day.

Dr. Prashant Bobhate, a highly experienced pulmonary hypertension specialist in Mumbai, India, has been at the forefront of this clinical innovation. Sotatercept, which has already shown significant promise in global clinical trials, is now delivering real-world results that are hard to ignore. This blog outlines the early experience of sotatercept use for the first four PAH patients in India, and the profound impact it has had on their quality of life.

The Indian PAH Context: Why This Matters

  • Younger Patients: The average age of diagnosis is about a decade earlier than in Europe.
  • Higher CTD-PAH Rates: More patients have PAH related to connective tissue diseases like systemic sclerosis.
  • Delayed Diagnosis: Many patients are diagnosed at later stages (WHO Functional Class III or IV).
    • Limited Access to Therapy: Parenteral prostanoids, key for high-risk cases, are not widely available in India.
    • Financial and Logistical Barriers: Long-term treatments like subcutaneous or intravenous therapy are difficult for many patients outside major cities

    Given these challenges, sotatercept’s subcutaneous dosing every three weeks offers a practical advantage, making it easier for patients to manage their treatment while potentially reducing the need for more intensive therapies. Dr. Prashant Bobhate, Pediatric Cardiologist in Mumbai, emphasizes the need for accessible treatment options, particularly in underserved areas, where patients face greater hurdles in managing their condition.

    Patient Profiles: The First Four Cases

    In this section, we highlight the first four cases of Pulmonary Arterial Hypertension (PAH) treated with sotatercept (brand name Winrevair) at Kokilaben Dhirubhai Ambani Hospital, Mumbai. These patients under the care of Dr Prashant Bobhate were suffering from severe PAH. Importantly, three of the patients were totally dependent on their wheelchairs at the time of the first visit. After continuing the treatment for over six months, the patients exhibited remarkable improvement that was comparable to the outcomes of the global STELLAR trial. This local experience highlights the high efficacy of sotatercept in bringing a positive change to the lives of patients with advanced PAH.

    Patient 1: Idiopathic PAH, WHO FC III, 34-Year-Old Female

    A young woman with a two-year history of idiopathic PAH (IPAH), on dual therapy (ambrisentan + tadalafil), with persistently poor functional status (6MWD: 265 m) and elevated NT-proBNP. Sotatercept was initiated at 0.3 mg/kg, with planned escalation to 0.7 mg/kg.

    Clinical Outcomes:

    • 6MWD improvement: +47 meters.
    • NT-proBNP decline: 38%.
    • Symptom improvement: Reported meaningful reduction in dyspnoea on exertion.
    • Tolerability: Escalated to target dose with no significant adverse events, only mild transient erythema at the injection site after the first dose.

    Patient 2: Systemic Sclerosis-Associated PAH, WHO FC III, 52-Year-Old Female

    A patient with limited cutaneous systemic sclerosis and PAH on triple oral therapy (ambrisentan + tadalafil + selexipag), with persistently intermediate-high risk hemodynamics. Given the disease progression and desire to avoid parenteral escalation, sotatercept was added.

    Clinical Outcomes:
    • Reduction in PVR: 28% at 16 weeks (RHC repeat).
    • WHO functional class improvement: From FC III to FC II.
    • Safety: Mild thrombocytopenia (platelet count nadir: 118 x 10^9/L), requiring a brief dose delay but no discontinuation.

    Patient 3: PAH Associated with Repaired Congenital Heart Disease, WHO FC II, 29-Year-Old Male

    A young male with repaired ventricular septal defect and residual PAH, on dual therapy, with an intermediate-risk profile based on the REVEAL Lite 2 score. Sotatercept was initiated due to persistent hemodynamic evidence of active vascular disease despite vasodilator therapy.

    Clinical Outcomes:

    • Improvement in exercise capacity: Notable improvement after 12 weeks.
    • Echocardiogram results: Reduction in estimated right ventricular systolic pressure.
    • Tolerability: The patient tolerated therapy without incident.This case highlights the potential role of sotatercept in PAH associated with congenital heart disease, a group not well-represented in pivotal trials.

    Patient 4: CTD-PAH (MCTD), WHO FC II-III, 44-Year-Old Female

    A patient with mixed connective tissue disease (MCTD) and PAH, on dual therapy, who had remained stable but not improved over 18 months. Sotatercept was added to target residual disease activity and vascular remodeling.

    Clinical Outcomes:

    • 6MWD improvement: +34 meters at 16 weeks.
    • NT-proBNP: Showed a downward trend.
    • Quality of life improvement: Patient reported improved daily function.
    • Hemoglobin: Rose from 11.8 g/dL to 13.4 g/dL, an expected effect of ActRIIA inhibition, no intervention needed.

    Expanding Beyond Treatment: Impactful Research and Collaboration

    At Kokilaben Dhirubhai Ambani Hospital, our journey with sotatercept is just one part of a larger commitment to improving outcomes for PAH patients in India. Led by Dr. Prashant Bobhate, a renowned Pediatric Cardiologist in Mumbai, we are pushing the boundaries of PAH research and collaboration:

    • Digital Stethoscope and AI-based Early Detection: We are developing innovative tools for early diagnosis of CHD and PAH using advanced digital stethoscopes and AI technologies to detect cardiovascular anomalies at the earliest stages, leading to better outcomes.
    • Multicenter Yoga Study: Initiated with 35 patients, this study focuses on the potential of yoga as an adjunct to traditional PAH treatments, helping patients improve functional capacity and quality of life.

    • ICMR-Recognized Centre of Excellence for PAH: Our institution is actively participating in three national clinical studies to further understand PAH and its treatment in the Indian context.

      These initiatives, combined with the positive clinical outcomes from sotatercept therapy, underscore the transformative changes happening in PAH care in India. We are not only providing better treatments but also striving to make early detection and holistic care a reality for all patients.

      Conclusion: A Pivotal Moment for Indian PAH Care

      Sotatercept is redefining the treatment of Pulmonary Arterial Hypertension (PAH) in India. Early experiences, including four patients at Kokilaben Dhirubhai Ambani Hospital, show significant improvements in functional capacity, haemodynamics, and disease risk profile, aligning with global trial results.

      For Indian clinicians, sotatercept represents a shift from vasodilatory management to disease modification, especially for patients with CTD-PAH and limited access to parenteral alternatives. As access expands and more real-world data is collected, larger registries will help assess its performance in India’s unique patient population.

      2025 marks a hopeful year for PAH care in India, with sotatercept leading the way in changing the treatment landscape and improving patient outcomes across the country.

      FAQs

      How is sotatercept different from other PAH drugs?
      Other than medications that dilate blood vessels, sotatercept works differently as it focuses on vascular remodeling by blocking activin signaling, thus hitting the root cause of PAH.
      Can sotatercept be used alone as a first, line treatment?
      In general, sotatercept is designed to be used with other PAH medications, and it is an add, on therapy rather than a solo treatment option.
      How is sotatercept given, and can I self, inject?
      Sotatercept is administered to patients via a subcutaneous injection every 21 days, and if properly trained, patients can perform the injections themselves at home.
      What monitoring is needed while on sotatercept?
      Monitoring will often include blood tests (hemoglobin, platelets), echocardiograms, 6, minute walk test, and NT, proBNP levels. Right heart catheterization might be planned at 6, 12 months.
      Are there any PAH subtypes that must not be treated with sotatercept?
      Sotatercept is not indicated for PAH Groups 2, 5 and in cases of severe thrombocytopenia, pericardial effusion, or pregnancy, caution should be exercised.
      What are the usual side effects in India?
      Increasing hemoglobin, decreasing platelet count, reactions at the injection site, headache, diarrhea, and skin changes (e.g. telangiectasias) are among the possibilities. Blood tests are done to keep these under control.
      Is sotatercept commercially available in India?

      Sotatercept has received FDA approval in the US, but there are still some issues with its availability in India. It is advisable to contact your medical professional or local healthcare provider for the most recent information on how to get it.

      How quickly will I be able to tell that sotatercept is working?
      One can usually observe better walking distance and functional status within 12, 24 weeks and changes in haemodynamics by 6 months.

      References:

      • Hoeper MM, et a1. STELLAR Trial. NEJM, 2023.
      • Rajagopal S, et a1. PULSAR Trial. NEJM Evidence, 2021.
      • HYPERION Trial. New England Journal ofMedicine, September 2025.
      • Mantoo MR, Majeed MW, Roy A. Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis. Indian Heart Journal, January 2026.
      • Gomez Rojas O, et a1. Real-world performance of sotatercept in PAH with cardiopulmonary comorbidities. Pulmonary Circulation, 2025.
      Top 5 Warning Signs of Pediatric Heart Failure

      Top 5 Warning Signs of Pediatric Heart Failure

      Pediatric heart failure may be defined as a state in which the heart fails in its primary role of circulating blood throughout the body. This might lead to serious complications if not detected early. Heart failure in children may not be immediately apparent until the condition worsens. This may be attributed to the early detection of the warning signs associated with the condition.

      “Since pediatric or infant heart failure can be a subtly developing condition, it is crucial for parents and caregivers to be vigilant and monitor their child’s health for signs such as fatigue and rapid breathing,” states Dr. Prashant Bobhate, a leading pediatric cardiologist in Mumbai. “If appropriately managed and treated, children with heart failure can lead a normal and healthy life.

      With over 12 years of experience in his field, Dr. Bobhate specializes in the management of pediatric heart failure in Mumbai, combining cutting-edge diagnostics with personalized treatment plans to ensure the best care for children at Kokilaben Dhirubhai Ambani Hospital. He is well-versed in dealing with both congenital and acquired conditions of the heart and is thus a professional of high repute for managing infant heart failure.

      Wondering what pediatric heart failure is and how it affects children? Here’s an overview of this serious condition.

      What is Pediatric Heart Failure?

      Pediatric heart failure occurs when a child’s heart is unable to pump blood efficiently, leading to insufficient blood flow to organs and tissues. It can be caused by congenital heart defects, infection, cardiomyopathy, or other heart-related conditions. Symptoms of pediatric heart failure can vary but often include fatigue, rapid breathing, and swelling. Timely intervention is crucial, as untreated heart failure can lead to long-term complications or even life-threatening conditions.

      Early detection and intervention are key to managing pediatric heart failure. Connect with an expert today for a comprehensive evaluation.

      How to spot the early signs of pediatric heart failure? Let’s explore the top warning signs you should look out for in your child.

      Warning Sign 1: Unexplained Fatigue and Weakness

      Unexplained fatigue and weakness are some of the first signs of pediatric heart failure. When the body’s organs are not receiving oxygen and nutrients due to poor blood flow, symptoms such as fatigue, weakness, and low energy can occur. Children may have difficulty engaging in play or sports due to extreme tiredness.

      Warning Sign 2: Rapid Breathing or Difficulty Breathing

      Rapid breathing, or difficulty breathing, is a hallmark symptom of heart failure in children. When the heart is not pumping blood properly, fluid can accumulate in the lungs, leading to breathing difficulties. This may be accompanied by shortness of breath, especially during physical activity or while lying down. Babies may show signs of labored breathing or irregular chest movements.

      Warning Sign 3: Swelling in the Legs, Abdomen, or Face

      If the heart fails to pump the blood properly, it results in the accumulation of fluids within the body and hence it causes swelling, especially in the lower limbs, abdomen or face. This is known as edema and can be a sign of heart failure’s progression. Swelling around the abdomen may also cause discomfort and difficulty in feeding, particularly in infants.

      Warning Sign 4: Poor Feeding and Weight Gain

      In infants and toddlers, poor feeding and poor weight gain are common indicators that may be seen in cases of heart failure. Inability to pump blood by the heart implies that less blood reaches the digestive tract. Children with heart failure may tire easily when being fed. They fail to gain proper nutrition.

      Warning Sign 5: Persistent Coughing or Wheezing

      Fluid accumulation in the lungs in children with heart failure can cause coughing or wheezing. Fluid accumulation within the tissues of the lungs happens when the pumping function of the heart is compromised. The cough, in most cases, is dry, persistent, and exacerbated when one is physically active or when sleeping.

      Unsure how pediatric cardiologists diagnose heart failure in children? Let’s dive into the diagnostic process and the tests involved.

      How Pediatric Cardiologists Diagnose Heart Failure in Children

      Wondering how pediatric heart failure is treated? Here are the treatment options that can help manage symptoms and improve quality of life.

      Treatment and Management Options for Pediatric Heart Failure

      • Medications

      Medications like diuretics, ACE inhibitors, and beta-blockers help reduce fluid buildup, lower blood pressure, and improve heart function.

      • Lifestyle Modifications

      A balanced diet, managing salt intake, and adequate rest are necessary for managing heart failure in children.

      • Cardiac Surgery or Interventions

      In severe cases, surgical interventions or catheter-based procedures may be needed to correct congenital heart defects or improve heart function.

      • Cardiac Rehabilitation

      After stabilization, children may benefit from a rehabilitation program to improve heart strength and endurance.

      Conclusion

      Recognizing the warning signs of pediatric heart failure early can make all the difference. Timely intervention, appropriate treatment, and ongoing care are crucial to improving outcomes and ensuring a better quality of life. Dr. Prashant Bobhate’s approach combines advanced diagnostics, personalized treatment plans, and compassionate care to help children with heart failure live healthier, more active lives.

      FAQs

      Can children live a normal life with heart failure?
      With early treatment and proper management, many children with heart failure lead active, fulfilling lives.
      What is the treatment for pediatric heart failure?

      Treatment includes medications like diuretics, ACE inhibitors, and beta-blockers, along with lifestyle adjustments and possible surgery.

      What are the risks of pediatric heart failure?

      Without treatment, pediatric heart failure can lead to severe complications, including heart failure, lung damage, and poor growth.

      Can heart failure in children be prevented?

      While some heart defects cannot be prevented, early detection and intervention can prevent complications and improve outcomes.

      Is pediatric heart failure the same as adult heart failure?

      No, pediatric heart failure often results from congenital defects, while adult heart failure is usually due to heart disease or lifestyle factors.

      Call Now Button